Canada · Delayed Price · Currency is CAD NexgenRx Statistics
Total Valuation
NexgenRx has a market cap or net worth of CAD 43.38 million. The enterprise value is 41.74 million.
| Market Cap | 43.38M |
| Enterprise Value | 41.74M |
Important Dates
The next estimated earnings date is Friday, November 20, 2026.
| Earnings Date | Nov 20, 2026 |
| Ex-Dividend Date | Aug 28, 2026 |
Share Statistics
NexgenRx has 71.12 million shares outstanding. The number of shares has decreased by -1.47% in one year.
| Current Share Class | 71.12M |
| Shares Outstanding | 71.12M |
| Shares Change (YoY) | -1.47% |
| Shares Change (QoQ) | +7.41% |
| Owned by Insiders (%) | 36.56% |
| Owned by Institutions (%) | n/a |
| Float | 44.81M |
Valuation Ratios
The trailing PE ratio is 19.68.
| PE Ratio | 19.68 |
| Forward PE | n/a |
| PS Ratio | 2.24 |
| PB Ratio | 4.62 |
| P/TBV Ratio | 7.84 |
| P/FCF Ratio | 14.24 |
| P/OCF Ratio | 13.33 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.22, with an EV/FCF ratio of 13.71.
| EV / Earnings | 17.64 |
| EV / Sales | 2.16 |
| EV / EBITDA | 12.22 |
| EV / EBIT | 11.54 |
| EV / FCF | 13.71 |
Financial Position
The company has a current ratio of 1.15, with a Debt / Equity ratio of 0.03.
| Current Ratio | 1.15 |
| Quick Ratio | 0.19 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.08 |
| Debt / FCF | 0.09 |
| Interest Coverage | 167.00 |
Financial Efficiency
Return on equity (ROE) is 30.10% and return on invested capital (ROIC) is 55.06%.
| Return on Equity (ROE) | 30.10% |
| Return on Assets (ROA) | 5.54% |
| Return on Invested Capital (ROIC) | 55.06% |
| Return on Capital Employed (ROCE) | 37.52% |
| Weighted Average Cost of Capital (WACC) | 7.08% |
| Revenue Per Employee | 967,080 |
| Profits Per Employee | 118,319 |
| Employee Count | 20 |
| Asset Turnover | 0.47 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NexgenRx has paid 645,841 in taxes.
| Income Tax | 645,841 |
| Effective Tax Rate | 19.71% |
Stock Price Statistics
The stock price has increased by +63.51% in the last 52 weeks. The beta is 0.52, so NexgenRx's price volatility has been lower than the market average.
| Beta (5Y) | 0.52 |
| 52-Week Price Change | +63.51% |
| 50-Day Moving Average | 0.52 |
| 200-Day Moving Average | 0.39 |
| Relative Strength Index (RSI) | 54.95 |
| Average Volume (20 Days) | 33,351 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NexgenRx had revenue of CAD 19.34 million and earned 2.37 million in profits. Earnings per share was 0.03.
| Revenue | 19.34M |
| Gross Profit | 16.42M |
| Operating Income | 3.62M |
| Pretax Income | 3.28M |
| Net Income | 2.37M |
| EBITDA | 3.32M |
| EBIT | 3.62M |
| Earnings Per Share (EPS) | 0.03 |
Balance Sheet
The company has 3.57 million in cash and 279,259 in debt, with a net cash position of 3.29 million or 0.05 per share.
| Cash & Cash Equivalents | 3.57M |
| Total Debt | 279,259 |
| Net Cash | 3.29M |
| Net Cash Per Share | 0.05 |
| Equity (Book Value) | 9.39M |
| Book Value Per Share | 0.11 |
| Working Capital | 5.54M |
Cash Flow
In the last 12 months, operating cash flow was 3.25 million and capital expenditures -208,040, giving a free cash flow of 3.05 million.
| Operating Cash Flow | 3.25M |
| Capital Expenditures | -208,040 |
| Depreciation & Amortization | 45,846 |
| Net Borrowing | -90,253 |
| Free Cash Flow | 3.05M |
| FCF Per Share | 0.04 |
Margins
Gross margin is 84.89%, with operating and profit margins of 18.70% and 13.60%.
| Gross Margin | 84.89% |
| Operating Margin | 18.70% |
| Pretax Margin | 16.94% |
| Profit Margin | 13.60% |
| EBITDA Margin | 17.18% |
| EBIT Margin | 18.70% |
| FCF Margin | 15.81% |
Dividends & Yields
This stock pays an annual dividend of 0.02, which amounts to a dividend yield of 2.46%.
| Dividend Per Share | 0.02 |
| Dividend Yield | 2.46% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 50.59% |
| Buyback Yield | 1.47% |
| Shareholder Yield | 3.93% |
| Earnings Yield | 5.45% |
| FCF Yield | 7.02% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NexgenRx has an Altman Z-Score of 1.26 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.26 |
| Piotroski F-Score | 6 |